| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,250 | 6,500 | 11:20 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 33,000 | 33 | |||
| 20,000 | 83 | |||
| 16,000 | 32 | |||
| 15,000 | 15 | |||
| 11,500 | 100 | |||
| 11,000 | 500 | |||
| 9,500 | 275 | |||
| 8,550 | 450 | |||
| 8,000 | 41 | |||
| 6,500 | 788 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 71 | 6,450 | |||
| 788 | 6,200 | |||
| 300 | 4,900 | |||
| 700 | 4,740 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.920 | 0,793 | 2.317 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 29.09.2026 | 16:58:11 | 6,450 | 29 |
| Tagesumsatz Xetra | 0,000 0,00 % | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | 4basebio meldet starken Anstieg der Auftragseingänge bei sinkendem Umsatz | 31 | Investing.com Deutsch | ||
| Mo | 4basebio reports 210% rise in H1 sales orders amid revenue decline | 10 | Investing.com | ||
| Mo | 4basebio PLC H1 Loss Rises | 6 | RTTNews | ||
| Mo | 4BASEBIO PLC: 4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company's Phase I Cell Therapy Program | 9 | Cision News | ||
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 07.09. | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine | 692 | PR Newswire | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine
PR Newswire
LONDON, United Kingdom, September 07
4basebio... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 07:03 | Adhoc: EvoNext Holdings SA: EvoNext Holdings SA publishes half-year report 2026 | EQS Group (EN) | EvoNext Holdings SA / Key word(s): Half Year Results
EvoNext Holdings SA publishes half-year report 2026
30-Sep-2026 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art.... ► Artikel lesen | |
| 00:34 | DBV Technologies S.A.: DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN Peanut Patch in Children Aged 4-7 Years | GlobeNewswire (Europe) | Châtillon, France, September 29, 2026
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN Peanut Patch in Children Aged 4-7 Years
The BLA is... ► Artikel lesen | |
| 00:42 | GenSight Biologics S.A.: GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates | Business Wire |
€6.5 million collected from paid early access programs; after recognition of rebates and a €4.3 million non-cash change in accounting estimate, reported IFRS revenue amounted to €(1.2) million.... ► Artikel lesen | |
| 07:33 | EQS-News: NanoRepro AG: Deutsche Kosmetikwerke AG wird Tochterunternehmen - Aktientausch sichert NanoRepro die Stimmrechtsmehrheit - Plattform-Struktur nimmt weiter Form an | EQS Group (DE) | EQS-News: NanoRepro AG
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung/Strategische Unternehmensentscheidung
NanoRepro AG: Deutsche Kosmetikwerke AG wird Tochterunternehmen... ► Artikel lesen | |
| 08:26 | Faron Pharmaceuticals Ltd: Convertible Bond Amortization Payment Deferred by Mutual Agreement With HCM | ACCESS Newswire | TURKU, FI / ACCESS Newswire / September 30, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company... ► Artikel lesen |